Venetoclax in Combination with Hypomethylating Agents for the Treatment of Treatment-Naive B/Myeloid Mixed-Phenotype Acute Leukemia and Relapsed/Refractory Acute Myeloid Leukemia: A Report of 3 Cases
B/myeloid mixed-phenotype acute leukemia (MPAL) is an uncommon and aggressive leukemia without well-established treatment guidelines and has an inferior outcome. Relapsed/refractory (R/R) acute myeloid leukemia (AML) that is ineligible for aggressive chemotherapy regimens and allogeneic hematopoietic stem-cell transplantation has an extremely poor prognosis. The novel regimen of venetoclax (VEN) combined with hypomethylating agents (HMAs) has a synergistic therapeutic effect and a tolerable safety profile, which has been officially approved by the US Food and Drug Administration (FDA) for newly diagnosed AML in adults who are 75 years or older or patients precluding intensive induction chemotherapy. For R/R and other rare types of AML, no consensus has been reached on the efficacy of VEN-HMA. In addition, there is no available report on treatment-naive B/myeloid MPAL with VEN-HMA. Herein, we present 3 cases of VEN-HMA in treatment-naive B/myeloid MPAL and R/R AML. Its potential efficacy is worthy of further exploration in future researches.
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Venetoclax in Combination with Hypomethylating Agents for the Treatment of Treatment-Naive B/Myeloid Mixed-Phenotype Acute Leukemia and Relapsed/Refractory Acute Myeloid Leukemia: A Report of 3 Cases ; volume:67 ; number:3 ; year:2022 ; pages:178-182 ; extent:5
Chemotherapy ; 67, Heft 3 (2022), 178-182 (gesamt 5)
- Urheber
-
Wang, Na
He, Jing
Liu, Fang
- DOI
-
10.1159/000519882
- URN
-
urn:nbn:de:101:1-2022090100250934632926
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:34 MESZ
Datenpartner
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wang, Na
- He, Jing
- Liu, Fang
Ähnliche Objekte (12)
Treatment of Relapsed Acute Myeloid Leukemia
Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia
Pathophysiology and treatment of NUP98-NSD1 acute myeloid leukemia
Repositioning of bromocriptine for treatment of acute myeloid leukemia
Post-Induction Treatment for Acute Myeloid Leukemia: Something Change?
Secondary acute myeloid leukemia after successful treatment for osteosarcoma
Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment
Pregnancy with acute myeloid leukemia
Venetoclax: A New Partner in the Novel Treatment Era for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia
Treatment of Relapsed Acute Myeloid Leukemia
Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia
Pathophysiology and treatment of NUP98-NSD1 acute myeloid leukemia
Repositioning of bromocriptine for treatment of acute myeloid leukemia
Post-Induction Treatment for Acute Myeloid Leukemia: Something Change?
Secondary acute myeloid leukemia after successful treatment for osteosarcoma
Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment
Pregnancy with acute myeloid leukemia
Venetoclax: A New Partner in the Novel Treatment Era for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia
Treatment of Relapsed Acute Myeloid Leukemia
Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia
Pathophysiology and treatment of NUP98-NSD1 acute myeloid leukemia
Repositioning of bromocriptine for treatment of acute myeloid leukemia
Post-Induction Treatment for Acute Myeloid Leukemia: Something Change?
Secondary acute myeloid leukemia after successful treatment for osteosarcoma
Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment
Pregnancy with acute myeloid leukemia
Venetoclax: A New Partner in the Novel Treatment Era for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab